BioCentury | Feb 27, 2021
Distillery Therapeutics
Trastuzumab-RNA polymerase inhibitor conjugate for breast cancer with low HER2 expression
...By Claire Quang, Staff Writer DISEASE CATEGORY: CancerINDICATION: Breast cancerAn antibody-drug conjugate comprising anti-HER2 antibody trastuzumab...
...inhibited growth with IC50 values 20-200 times lower than marketed ADC Kadcyla ado-trastuzumab emtansine, which conjugates trastuzumab...
...DM1. In a xenograft mouse model of TNBC with 17p loss and low HER2 expression, the trastuzumab-α-amanitin...
...inhibited growth with IC50 values 20-200 times lower than marketed ADC Kadcyla ado-trastuzumab emtansine, which conjugates trastuzumab...
...DM1. In a xenograft mouse model of TNBC with 17p loss and low HER2 expression, the trastuzumab-α-amanitin...